Cue Biopharma Debuts With $26 Million in Invested Capital to Develop Next-Generation Biologics to...

Two years after being founded, Cambridge, Massachusetts, upstart Cue Biopharma has raised $26 million to help advance its work using biologics to target T cell receptors to help patients’ immune systems defeat cancer and autoimmune diseases.

Atlas Genetics Raises $35m In Series D Fundraising

Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces completion of its Series D financing, raising $35 million from a syndicate including all Series C Investors and one new investor, Wondfo Biotech.



Twitter LinkedIn 


WuXi AppTec Expands Site in the United States for Drug Development...

We are pleased to announce the grand opening of WuXi AppTec's expanded Laboratory Testing Division (LTD) facility in New Jersey. The expansion will double total...